Empagliflozin, linagliptin, metformin hydrochloride
Trijardy XR is a prescription medication combining empagliflozin, linagliptin, and metformin to help manage type 2 diabetes by lowering blood sugar levels. It's taken orally as extended-release tablets in various strengths. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[ "009:10" ] |
| contactPoint |
{ "fn": "Division of Drug Information", "@type": "vcard:Contact", "hasEmail": "mailto:druginfo@fda.hhs.gov" } |
| description | Trijardy XR is a prescription medication combining empagliflozin, linagliptin, and metformin to help manage type 2 diabetes by lowering blood sugar levels. It's taken orally as extended-release tablets in various strengths. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[ { "@type": "dcat:Distribution", "title": "Empagliflozin, linagliptin, metformin hydrochloride", "mediaType": "text/html", "description": " Access the FDA dataset for Empagliflozin, linagliptin, metformin hydrochloride — ANDA 212614 submitted by Mylan Institutional LLC ", "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212614" } ] |
| identifier | ANDA212614 |
| issued | 2016-09-16 |
| keyword |
[ "drug-information", "drug-manufacturers", "drug-safety", "medications", "pharmaceuticals" ] |
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[ "009:002" ] |
| publisher |
{ "name": "U.S. Food and Drug Administration", "@type": "org:Organization" } |
| theme |
[ "FDA" ] |
| title | Empagliflozin, linagliptin, metformin hydrochloride |
